CLOs on the Move

Aqualung Therapeutics

www.aqualungtherapeutics.com

 
Aqualung Therapeutics (ALT) is developing multi-pronged strategies to address the development of severe lung inflammation which is essential to the severity and outcomes of acute and chronic lung disorders such as acute lung injury, ventilator-induced lung injury (VILI), idiopathic pulmonary fibrosis, and pulmonary hypertension.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Human Longevity

Human Longevity, Inc. ™ (HLI) is the genomics-based, health intelligence company creating the world`s largest and most comprehensive database of whole genome, phenotype and clinical data. HLI is developing and applying large scale computing and machine learning to make novel discoveries from these data to generate personalized health insights. Our goal is to extend healthy human life by revolutionizing human health and transforming the practice of medicine. Our DNA determines so much about each of us, but other factors can also influence our health. HLI is focused on compiling and analyzing more genotypic and phenotypic data because the combination of both enables us —to generate unprecedented insights and accelerate our understanding into what makes us who we are and what we can change for a life better lived.

MARATHONLS

Marathon Life Sciences Laboratory Solutions at the Speed of Science Learn more Our Lab Supplies Line Cell Strainer Download Catalogadd to cart Tissue Culture Plates Download Catalog 15/50mL Centrifuge Tubes Download Catalog Petri Dishes Download Catalo...

XtalPi

XtalPi is a pharmaceutical technology company that is reinventing the industry’s approach to drug research and development with its Intelligent Digital Drug Discovery and Development (ID4) platform.

Kansas City University College of Dental Medicine

Kansas City University announced June 4 its plans to open a College of Dental Medicine on its Joplin, Missouri, campus, with an anticipated groundbreaking in 2020. The goal is to seat a class of 80 students in 2022.

Axial Therapeutics

We are harnessing the #gut brain axis & the #CNS to develop a new class of therapeutics for people with neurological diseases & disorders